Secukinumab showed sustained improvements for PsA after 3 years

12:19 EDT 29 Jun 2017 | Healio

MADRID — Secukinumab showed sustained improvements in patients with ankylosing spondylitis and in patients with psoriatic arthritis after 3 years, according to findings presented at the EULAR Annual Congress. “These data reconfirm that Cosentyx provides patients with long-lasting relief from the symptoms of psoriatic arthritis, as well as now demonstrating rapid pain relief from psoriatic arthritis,” Vas Narasimhan, global head of drug development and chief medical officer of Novartis, said in a press release. “We are pleased that Cosentyx continues to provide sustained benefits for patients with psoriasis, psoriatic arthritis and ankylosing spondylitis.”

Original Article: Secukinumab showed sustained improvements for PsA after 3 years


More From BioPortfolio on "Secukinumab showed sustained improvements for PsA after 3 years"

Quick Search


Relevant Topics

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...

Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...